Bianca Lederer
Overview
Explore the profile of Bianca Lederer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):23.
PMID: 37029138
This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant...
2.
Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, et al.
PLoS One
. 2021 Sep;
16(9):e0257142.
PMID: 34469495
[This corrects the article DOI: 10.1371/journal.pone.0238021.].
3.
Marme F, Solbach C, Michel L, Schneeweiss A, Blohmer J, Huober J, et al.
Eur J Cancer
. 2021 Jun;
153:203-212.
PMID: 34186505
Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with superior survival. This association is strongest in triple-negative breast cancer (TNBC). The CPS + EG system, based on...
4.
Villegas S, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al.
Eur J Cancer
. 2021 Mar;
148:159-170.
PMID: 33743484
Aim: To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and...
5.
Furlanetto J, Mobus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, et al.
Eur J Cancer
. 2021 Jan;
145:44-52.
PMID: 33423006
Background: BRCA1 and BRCA2 play a central role in DNA repair. Therefore, patients harbouring germline (g) BRCA1/2 mutations (m) treated with chemotherapy might be at higher risk of haematological toxicities....
6.
Pohl-Rescigno E, Hauke J, Loibl S, Mobus V, Denkert C, Fasching P, et al.
JAMA Oncol
. 2020 Mar;
6(5):744-748.
PMID: 32163106
Importance: The GeparOcto randomized clinical trial compared the efficacy of 2 neoadjuvant breast cancer (BC) treatment regimens: sequential intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) vs weekly paclitaxel and nonpegylated...
7.
Guo S, Loibl S, von Minckwitz G, Darb-Esfahani S, Lederer B, Denkert C
Cancer Res Treat
. 2020 Feb;
52(3):689-696.
PMID: 32019278
Purpose: PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CA mutation was predictive for pathological complete response (pCR) in human epidermal growth factor...
8.
Heitz F, Kummel S, Lederer B, Solbach C, Engels K, Ataseven B, et al.
Geburtshilfe Frauenheilkd
. 2019 Oct;
79(10):1110-1117.
PMID: 31656321
Oestrogen receptor beta (ER-β) is abundantly expressed in breast cancer (BC), but its impact on neoadjuvant chemotherapy outcome is unknown. Patients treated in the neoadjuvant GeparTrio trial with available tissue...
9.
Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31443252
: Remodeling of extracellular matrix through collagen degradation is a crucial step in the metastatic cascade. The aim of this study was to evaluate the potential clinical relevance of the...
10.
Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, et al.
Ann Surg Oncol
. 2019 Jul;
26(12):3892-3901.
PMID: 31350646
Background: The impact of locoregional radiotherapy (RT) after neoadjuvant chemotherapy (NACT) and mastectomy in breast cancer patients is currently unclear. Several publications have suggested that patients with a favorable response...